Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 16Colorectal Neoplasms 3Postoperative Complications 2Anastomotic Leak 2Transfusion Reaction 1Recurrence 1Rectal Cancer Stage T1-T2 1Pathologic Complete Response 1Gastrointestinal Neoplasms 1Colonic Neoplasms 1Colitis, Ulcerative 1Colitis, Ischemic 1Coitus 1

Interventions

pembrolizumab 4Trastuzumab 4Oxaliplatin 4Fluorouracil 4Cyclophosphamide 4Carboplatin 4Radiotherapy 3Paclitaxel 3Endoscopy 3Docetaxel 3Cytarabine 3Chemoradiotherapy 3Capecitabine 3toripalimab 2Tretinoin 2Surgical Procedures, Operative 2Standard of Care 2Observation 2Neoadjuvant Therapy 2Metformin 2Magnetic Resonance Imaging 2Leucovorin 2Irinotecan 2Immunotherapy 2Immune Checkpoint Inhibitors 2Epirubicin 2Drug Therapy 2Doxorubicin 2Cisplatin 2Blood Specimen Collection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Pathologic Complete Response × Proctectomy × Clear all
NCT03601689 2018-07-26

Predictive Factors of Disease-free Survival After Complete Pathological Response to Neoadjuvant Radiotherapy in Rectal Adenocarcinoma

Moroccan Society of Surgery

Completed
84 enrolled
Gastrointestinal

Pathologic Complete Response, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡